Food Drug Administration Archives - Carey Danis & Lowe

NuvaRing & The Plight of One Family

By | NuvaRing, Pharmaceutical litigation, Uncategorized

nuvaring_lawsuit_heart_attackA Tennessee Valley family gathered together for the 2013 holiday season, and everyone was in good spirits. However, a mere five days later, the family was saddened by the news that one of their own had succumbed to a blood clot. The family member, Angela Miller, was only 28 years old.

According to a news story from WTVC News Channel 9 in the Tennessee Valley, Miller had been using a contraceptive device called the NuvaRing. In their report, WTVC cites data from the U.S. Food & Drug Administration on NuvaRing fatality and injury numbers. Those records show 224 deaths and 3,000 serious injuries.

Manufactured by Merck, the NuvaRing was introduced in 2002, and has been associated with blood clots, heart attack, stroke, pulmonary embolism, and deep vein thrombosis (DVT).

Following their loss, the Miller family began a campaign to raise awareness about NuvaRing side effects with the hopes that what befell their family would not happen to any other families.

Carey Danis & Lowe Can Help

As a national law firm specializing in defective drug litigation, Carey Danis & Lowe represents individuals and families that have been harmed by the NuvaRing. Our personal injury lawyers understand the pain and suffering that defective medical products cause, and because of that, our lawyers are dedicated to providing our clients with superior legal assistance.

If you or someone you love has been injured by the NuvaRing, Carey Danis & Lowe is available to discuss legal options and compensation eligibility now. Our law firm offers free initial case evaluations.

Share your NuvaRing story with a Carey Danis & Lowe lawyer today. Call 800.721.2519, or complete a confidential personal injury claim form.

European Medicines Agency’s Takes a Stand on Actos

By | Actos, Pharmaceutical litigation, Uncategorized

Submit Your Claim

[contact-form-7 id=”1660″ title=”mirena”]

European Medicines Agency's Takes a Stand on ActosThe European Medicines Agency made an effort to provide more detail on its conclusion regarding the safety of drugs containing pioglitazone, including the diabetes drug Actos. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded in July 2011 that in patients taking medicines containing pioglitazone, such as Actos, their researchers observed an increased risk in the development of bladder cancer.

Though the European Medicines Agency recognizes the risk for patients to develop bladder cancer, they are still recommending that doctors prescribe drugs such as Actos, and other pioglitazone medications, for the treatment of type 2 diabetes.

Their recommendation does place some patients at an increased risk of developing bladder cancer, and in recognizing the threat of cancer development, the European Medicines Agency has added to their stance on pioglitazone medications that doctors prescribing such drugs must closely monitor their patients for any signs of bladder cancer.

Furthermore, the European Medicines Agency recommended that doctors should use careful discretion in determining when to prescribe drugs such as Actos.

In recognizing the link between Actos and increased risk of bladder cancer, France and Germany have made efforts to halt sales of Actos and other pioglitazone medications.

In the United States, the U.S. Food & Drug Administration is currently analyzing data being collected in a 10 year study conducted by Kaiser Permanente Northern California and Takeda Pharmaceuticals Inc., the manufacturer of Actos. After its review of data from the Kaiser Permanente and Takeda study, the FDA will make a conclusion regarding the safety of Actos and other pioglitazone medications.

Currently, the FDA recommends that Actos not be prescribed to patients who are currently suffering from bladder cancer. Signs of bladder cancer include hematuria, or blood present in urine, painful urination, back and pelvic pain, and a frequent need to urinate. If you are taking Actos and are experiencing any of these bladder cancer symptoms, contact your healthcare provider as soon as possible.

In light of the dangers associated with Actos and other pioglitazone medications, lawyers at Carey Danis & Lowe are currently accepting Actos claims.

If you or someone you love has developed bladder cancer as a result of taking Actos or pioglitazone, understand that you do not have to suffer alone. Our experienced pharmaceutical litigation lawyers work closely with clients to win them much deserved justice and compensation.

Receive a free legal consultation about an Actos lawsuit today by calling a lawyer at Carey Danis & Lowe at 800.721.2519.